Fucoidan reduces Schistosoma mansoni worm burden and inflammation in mice, showing timing-dependent efficacy
Background
Schistosomiasis, caused by parasitic flatworms like Schistosoma mansoni, is a major neglected tropical disease affecting millions globally. Chronic infection leads to severe granulomatous inflammation, fibrosis, and progressive liver damage, which can be fatal. Current treatments often target adult worms, but there's a critical need for interventions that can mitigate early-stage pathology and prevent long-term organ damage. Understanding novel compounds that can modulate the host's inflammatory response and reduce parasite burden, especially during immature stages, is crucial for developing more comprehensive therapeutic strategies.
Study Design
Researchers evaluated Fucoidan (FUC), a sulfated polysaccharide, in 48 CD-1 Swiss male albino mice infected with Schistosoma mansoni. Mice were divided into six groups: an infected untreated control, a praziquantel-treated group, and four Fucoidan-treated groups. Fucoidan treatment was initiated at 7, 21, 35, or 42 days post-infection (dpi), targeting different immature stages of the parasite. Primary endpoints included assessment of worm burden, granuloma size, and fibrosis in liver tissue, alongside quantification of inflammatory cytokine expression using methods like qPCR for TNF-α, IL-1β, and iNOS levels.
Results
Treatment with Fucoidan significantly reduced key pathological markers associated with S. mansoni infection. Specifically, FUC administration led to a significant reduction in overall worm burden, indicating direct anti-helminthic activity. Furthermore, the compound effectively decreased granuloma size and liver fibrosis, mitigating the severe tissue damage characteristic of schistosomiasis. This was accompanied by a significant downregulation of pro-inflammatory mediators, including TNF-α, IL-1β, and iNOS expression in the liver, suggesting a potent anti-inflammatory effect. The efficacy of Fucoidan was highly dependent on the timing of intervention. > The strongest antipathological effects were consistently observed with early-to-mid treatments, particularly FUC7, FUC21, and FUC35 groups, which showed superior reductions in disease severity. In contrast, the FUC42 group exhibited weaker benefits, highlighting the importance of early intervention against immature parasite stages.
Key Findings
- Fucoidan treatment significantly reduced
Schistosoma mansoniworm burden in infected mice. - Granuloma size and liver fibrosis were significantly decreased by Fucoidan.
- Expression of pro-inflammatory markers
TNF-α,IL-1β, andiNOSin liver tissue was significantly reduced. - Strongest anti-pathological effects were observed with early-to-mid treatments (FUC7, FUC21, FUC35).
- Efficacy was timing-dependent, with FUC42 showing weaker benefits against mature infection.
Why It Matters
This research highlights Fucoidan as a promising candidate for early intervention in Schistosoma mansoni infection, offering a potential strategy to prevent the severe inflammatory and fibrotic pathology that leads to liver damage. For those interested in natural compounds with broad anti-inflammatory and anti-parasitic properties, Fucoidan's efficacy against immature S. mansoni stages is a significant finding. It suggests a shift from solely targeting adult worms to a more proactive approach that could limit disease progression from the outset. While this is a preclinical animal study, the timing-dependent efficacy suggests that future human protocols might benefit from early administration, potentially as a prophylactic or early therapeutic agent in endemic areas, complementing existing treatments.
fucoidan
schistosomiasis
anti-inflammatory
anti-fibrotic
neglected-tropical-disease
preclinical-animal